Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash & Current Investments: 2019-2024

Historic Cash & Current Investments for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $681.1 million.

  • BridgeBio Pharma's Cash & Current Investments rose 59.20% to $645.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 37.58%. This contributed to the annual value of $681.1 million for FY2024, which is 56.62% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Cash & Current Investments of $681.1 million as of FY2024, which was up 56.62% from $434.9 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Cash & Current Investments ranged from a high of $681.1 million in FY2024 and a low of $356.2 million during FY2020.
  • Moreover, its 3-year median value for Cash & Current Investments was $434.9 million (2023), whereas its average is $510.2 million.
  • In the last 5 years, BridgeBio Pharma's Cash & Current Investments declined by 2.08% in 2020 and then soared by 56.62% in 2024.
  • BridgeBio Pharma's Cash & Current Investments (Yearly) stood at $356.2 million in 2020, then increased by 10.59% to $393.9 million in 2021, then increased by 5.25% to $414.6 million in 2022, then climbed by 4.89% to $434.9 million in 2023, then skyrocketed by 56.62% to $681.1 million in 2024.